RankAlpha logo

AFYA

AI Memo

Afya

As of 2026-11-03/Confidence medium
Open tickerBack to Memos
Data freshness
AI Memo
As of 2026-11-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
—
Confidence
medium
Horizon
—
Key catalyst
2026 guidance and margin delivery • 2026-12-31
Base target: $11 / p=45% prob
Biggest risk
Margin compression, investment spending, regulatory or shareholder delays, and variable share consideration could offset operating growth. Ineligible holders face post-closing sale mechanics rather than direct receipt of Yduqs shares. [#PR-2026-09-23] SEC-filed Afya announcement
Invalidation
Break below $8 or thesis failure.
What would change my mind?
Medical-school tuition and enrollment growth, cash generation, and completion of the proposed combination could support upside. These are conditional outcomes, not a confirmed rerating. [#PR-2026-08-13] SEC-filed Afya results
Research note
Recommendation
—
Confidence
medium
As of
2026-11-03
Base target
$11
p=45%
Bull target
$15
p=25%
Bear target
$8
p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Medical-seat and tuition conversion
  • Medical-school tuition and enrollment growth, cash generation, and completion of the proposed combination could support upside.
  • These are conditional outcomes, not a confirmed rerating.
BearKey bullets
  • Authorized medical seats may not translate promptly into enrolled students or revenue.
  • [#PR-2026-09-18] SEC-filed seat announcement
  • First-half adjusted EBITDA margin declined 190 basis points year over year; continued-education economics and investment spending may pressure guidance delivery.
WatchKey bullets
  • 2026 guidance and margin delivery

Summary

High-level snapshot

Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
-
Base case: $11 (p=45%)
Target spread vs base: +43% / -29%
Scenario probabilities
Bull Target: $15 (p=25%)Base Target: $11 (p=45%)Bear Target: $8 (p=30%)
Commentary
Merger coverage dominates the supplied headlines, but a reliable post-announcement price reaction and verified analyst target or estimate revisions are unavailable. Social coverage, options skew, short interest and employee sentiment are unavailable; zero fields denote missing data, not neutral readings. Primary transaction and operating disclosures support monitoring, while uncertain approvals, variable consideration and margin recovery limit conviction. The deterministic prior is neutral, with high uncertainty and low catalyst density.
As of 2026-11-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
Medical-school tuition and enrollment growth, cash generation, and completion of the proposed combination could support upside. These are conditional outcomes, not a confirmed rerating. [#PR-2026-08-13] SEC-filed Afya results
Bear Case
Margin compression, investment spending, regulatory or shareholder delays, and variable share consideration could offset operating growth. Ineligible holders face post-closing sale mechanics rather than direct receipt of Yduqs shares. [#PR-2026-09-23] SEC-filed Afya announcement

Drivers

Scannable catalysts and supporting factors

  • Medical-seat and tuition conversion

Scenarios

Bull Target (Scenario probability)
$15 / p=25% prob
Base Target (Scenario probability)
$11 / p=45% prob
Bear Target (Scenario probability)
$8 / p=30% prob
Analysis 2026-11-03 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-12-31
    2026 guidance and margin delivery
    Afya reaffirmed 2026 revenue guidance of R$3.95–4.10 billion and adjusted EBITDA guidance of R$1.70–1.80 billion. First-half revenue rose 7.0%, but adjusted EBITDA rose 2.8% and margin contracted 190 basis points to 46.2%. The 2026 year-end results will test whether growth offsets investment spending; December 31 is the fiscal-period end, not a confirmed reporting date. [#PR-2026-08-13] SEC-filed Afya results
    Prob 55.00% • Move 6.00% • Priced-in 50.00%
  • EVENT2028-03-31
    Yduqs merger approvals and exchange value
    Afya agreed to exchange each share for 6.408347 new Yduqs shares. Shareholder and Brazilian antitrust approvals remain outstanding; the agreement sets March 31, 2028 as the latest consummation date, subject to extensions. Consideration is not a fixed U.S.-dollar cash price, so Yduqs shares and BRL/USD affect its value. The proposed merger has not closed. [#PR-2026-09-23] SEC-filed Afya announcement
    Prob 60.00% • Move 12.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

  • Medical-seat and tuition conversion
    2027-06-30
    Afya reported 3,768 operating medical seats and 3.9% growth in medical-school net average ticket for the first half. A subsequent authorization added 17 Cruzeiro do Sul seats, bringing approved seats to 3,785. Enrollment and revenue conversion—not authorization alone—are the investment test. The date is an illustrative monitoring horizon, not company guidance. [#PR-2026-08-13] SEC-filed Afya results [#PR-2026-09-18] SEC-filed seat announcement
    Prob 60% • Move 5% • Priced-in 50%

Risks

  • Authorized medical seats may not translate promptly into enrolled students or revenue. [#PR-2026-09-18] SEC-filed seat announcement
  • First-half adjusted EBITDA margin declined 190 basis points year over year; continued-education economics and investment spending may pressure guidance delivery. [#PR-2026-08-13] SEC-filed Afya results
  • Fixed-share consideration exposes Afya holders to Yduqs share-price and BRL/USD moves; ineligible holders may instead receive uncertain net proceeds from a post-closing sale. [#PR-2026-09-23] SEC-filed Afya announcement
  • Shareholder, antitrust, third-party-consent and closing-condition risk for the proposed Yduqs merger; Nasdaq delisting is contemplated only if it closes. [#PR-2026-09-23] SEC-filed Afya announcement

Peers

SymbolSummary
COURAdjacent education-services company, but online-learning economics are not a direct benchmark for Afya's regulated Brazilian medical seats and tuition. Peer comparability is weak.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-11-03